CD73 expression as a resistance mechanism in advanced <i>EGFR-</i>mutated non-small cell lung cancer.

However, patients who developed T790M-positive disease after progression on previous EGFR-TKIs and had a high expression (above median) of either CD73, CD39, HLA-E or NKp46 in the pre-osi biopsy specimen, showed a trend towards shorter PFS when treated with osimertinib than the patients with biopsies with low expression (under median) of any of the markers ( Table 2 ).

also in 53,322 other papers